---
title: "Fundly.ai’s ~$4.9M: Accel and Multiply Expand India Pharma Commerce Rails"
description: "Mumbai’s Fundly.ai raised ~$4M equity led by Accel and Multiply Ventures plus ~$0.9M venture debt (~$4.9M) — doubling down after a 2023 $3M seed as it stacks B2B commerce, payments, and credit for pharma distribution."
date: 2026-09-08T00:00:00.000Z
tags: ["2026-vc-news", "startup-funding", "venture-capital", "fintech", "india-vc", "healthtech"]
source: https://venturecapitaltracker.com/2026-fundly-ai-4m-accel-multiply-pharma-rails
---

# Fundly.ai’s ~$4.9M: Accel and Multiply Expand India Pharma Commerce Rails

> Mumbai’s Fundly.ai raised ~$4M equity led by Accel and Multiply Ventures plus ~$0.9M venture debt (~$4.9M) — doubling down after a 2023 $3M seed as it stacks B2B commerce, payments, and credit for pharma distribution.

**Accel** and **Multiply Ventures** led roughly **$4 million** of new equity into Mumbai’s **Fundly.ai** on **September 8, 2026**, with former RBL Bank executive director **Rajeev Ahuja** and other angels — plus about **$0.9 million** venture debt, for **~$4.9 million** combined (**Indian Startup Times**). The print follows Accel’s **$3 million** 2023 seed.

**Spine:** India pharma distribution still runs on fragmented ordering and working capital — Fundly is trying to own the **commerce + payments + credit** stack for the same retailers Accel already underwrote once.

## Key facts

| Field | Detail |
| --- | --- |
| Company | [Fundly.ai](/startup/fundly-ai) ([fundly.ai](https://fundly.ai/)) |
| Founders | Amit Chawla, Shreeram Ramanathan (2021) |
| Structure | **~$4M equity** + **~$0.9M** venture debt ≈ **~$4.9M** |
| Leads | Accel, Multiply Ventures (existing) |
| Prior | **$3M** seed (2023, Accel-led) |
| Use of proceeds | Expand digital commerce, payments, and credit across pharma supply chain |
| Valuation / ARR | **Not disclosed** |

## Who uses the product — and for what job

**Users:** pharma retailers and distributors that procure stock, settle invoices, and need short-duration working capital.

**Job:** collapse three vendors (ordering portal, payments rail, lender) into one platform so daily inventory turns are not blocked by credit or reconciliation lag.

Fundly began as supply-chain finance and broadened — the raise funds that full-stack pitch, not a pure lender expansion alone.

## Why Accel and Multiply — fit

Accel’s second cheque signals category conviction in **vertical fintech rails** where distribution density matters more than consumer brand spend. Multiply’s repeat participation reinforces India SMB/credit adjacency. **Do not** treat Accel as a linked `/fund/` page — it is absent from our directory.

Debt alongside equity is a tell: growth that needs **balance-sheet capacity** for credit books, not only SaaS burn.

## What is not proven

- GMV, take rate, NPL, and retailer count were **not disclosed** in the IST coverage reviewed.
- Round stage labeling is inferred (post-seed follow-on); company did not publish a Series letter in the piece cited.
- Venture-debt terms (lender, covenants) were **not named**.

## Implication

Fundly’s next diligence gate is **credit performance through the cycle**, not feature breadth. If embedded loans stay clean while commerce volume rises, Accel’s double-down looks cheap; if credit losses climb, the $0.9M debt facility becomes the story.

### Sources

1. [Indian Startup Times](https://www.indianstartuptimes.com/investment/fundly-ai-raises-4-million-to-expand-b2b-pharma-distribution-platform/)
2. [Fundly.ai](https://fundly.ai/)

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.